DYRK1A and cancer: Using multiple models of PARPi-resistant HGSC, this study demonstrates the use of a pan-CLK/DYRK inhibitor, SM08502, to significantly inhibit WNT/TCF signaling, reduce cancer cell viability, and modulate alternative splicing.